BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $557
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $545
Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR), Sarepta Therapeutics (SRPT) and Vertex Pharmaceuticals (VRTX)
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX)
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $510
Vertex Pharmaceuticals (VRTX) Gets a Hold From Bernstein
Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
Vertex Pharmaceuticals Analyst Ratings
William Blair Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals: Strategic Advancements and Promising Market Potential Drive Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Globus Medical (GMED) and Vertex Pharmaceuticals (VRTX)
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $512
Analysts' Top Healthcare Picks: BridgeBio Pharma (BBIO), Vertex Pharmaceuticals (VRTX)
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)